Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)

Volume 15, 2 Issues, 2017

Download PDF Flyer

Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens

Anti-Infective Agents, 6(4): 263-272.

Author(s): W. Magliani, S. Conti, D. L. Maffei, L. Ravanetti and L Polonelli.

Affiliation: Sezione di Microbiologia,Dipartimento di Patologia e Medicina di Laboratorio, Viale A. Gramsci 14,43100 Parma, Italy.


This review describes the novel experimental observations on antimicrobial and antiviral activities of a synthetic killer peptide (KP), derived from the variable region of a recombinant antiidiotypic antibody mimicking a widespectrum microbicidal yeast killer toxin (KT). The rationale, generation and experimental use of KT-like antiidiotypic microbicidal antibodies and mimotopes against the opportunistic pathogen Candida albicans were previously discussed. Recently, KP has demonstrated an in vitro microbicidal activity against such diverse AIDS-related pathogens as Cryptococcus neoformans, Pneumocystis carinii, Paracoccidioides brasiliensis, Acanthamoeba castellanii, Leishmania major and L. infantum, Mycobacterium tuberculosis and other bacteria. KP also demonstrated a significant therapeutic effect against experimental vaginal and systemic candidiasis, disseminated cryptococcosis, and paracoccidioidomycosis. The observation that KP may inhibit ex-vivo HIV-1 replication, opens new perspectives in the simultaneous treatment of HIV-1 and AIDS-related opportunistic pathogens. Despite the advent of highly active antiretroviral therapy (HAART) has dramatically improved the prognosis and quality of life of HIV-infected people, opportunistic infections still remain the most common cause of death. Current combination regimens, moreover, remain hampered by issues of patient compliance, tolerance, long term toxicity, incomplete viral suppression, and drug resistance, which are often responsible for therapy failure. There is an urgent need for new therapeutic strategies in AIDS. The potential use of KP, endowed with minimal toxicity, ease of production and manipulation (such as its production in planta), differential antimicrobial and antiviral mechanism of action, and modulation of immune cell populations are discussed.


Yeast killer toxin, killer mimotopes, antimicrobial therapy, antiidiotypic antibodies, anti-HIV therapy, opportunistic infections.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 4
First Page: 263
Last Page: 272
Page Count: 10
DOI: 10.2174/187152107782023060
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science